New Therapy Offers Potential Cure for Type 1 Diabetes by Protecting Insulin-Producing Cells

A groundbreaking approach to treating type 1 diabetes (T1D) is underway at the Medical University of South Carolina (MUSC), offering a potential path toward a cure. Researchers, led by Leonardo Ferreira, Ph.D., are combining stem cell science, immunology and transplantation research with $1 million in funding from Breakthrough T1D, a leading global research and advocacy organization. The ambitious goal: to restore the body’s ability to regulate blood sugar without the need for lifelong insulin injections and the risks associated with immunosuppressant drugs.

Engineering Immune Tolerance: A Recent Strategy

Type 1 diabetes is an autoimmune disease where the body’s immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. Currently, people with T1D must carefully manage their blood glucose levels through regular monitoring and insulin therapy. According to the Centers for Disease Control and Prevention, approximately 1.5 million Americans are living with this condition, and long-term complications can include nerve damage, blindness, and even life-threatening events. CDC Type 1 Diabetes

Dr. Ferreira’s team is focusing on a two-pronged cellular therapy. The first part addresses the shortage of beta cells. Rather than relying solely on donor tissue – which is limited – they are producing insulin-producing islet cells in the laboratory using stem cell technology. This offers the potential for a scalable and reliable supply of cells for treatment. The second, and perhaps more innovative, component involves “reprogramming” the immune system to accept these transplanted cells.

The key lies in regulatory T cells, or Tregs. These cells act as the immune system’s “bodyguards,” preventing it from overreacting and attacking healthy tissues. Ferreira’s expertise lies in engineering these Tregs using chimeric antigen receptors (CARs). These CARs are designed to guide the Tregs specifically to the transplanted beta cells, essentially telling the immune system to leave them alone. This targeted approach aims to create a protective shield around the new cells, preventing immune rejection.

The Role of Tregs and CAR Technology

“Once there, the engineered Tregs function as targeted ‘bodyguards,’ protecting the beta cells from immune attack,” explains the research, as detailed in a SciTechDaily report. The interaction between the CAR on the Treg and a specific protein on the beta cell is described as a “lock and key” mechanism, signaling the immune system to stand down. This precise targeting is crucial, as it minimizes the risk of widespread immune suppression, which can have serious side effects.

This approach is particularly significant because it could eliminate the need for long-term immunosuppressive drugs, which are currently required after most transplants. These drugs, although necessary to prevent rejection, carry significant risks, especially for children. Avoiding these drugs would dramatically improve the quality of life for people living with T1D.

Building on Previous Research

The current project builds on earlier work supported by a 2021 Discovery Pilot grant from the South Carolina Clinical & Translational Research Institute (SCTR). This initial funding allowed Ferreira and Holger Russ, Ph.D., of the University of Florida – a leading expert in stem cell research – to start collaborating and lay the groundwork for the larger, more ambitious project now underway. Russ’s expertise in generating a virtually unlimited supply of islet cells from stem cells is a critical component of the strategy. MUSC News

The team as well includes Michael Brehm, Ph.D., of the University of Massachusetts Medical School, who has developed humanized mouse models that allow researchers to study human immune and metabolic responses to T1D in a controlled setting. These models are essential for testing the efficacy and safety of the new therapy before it can be tested in humans.

What Remains to Be Seen

While the initial results are promising, several key questions remain. Researchers are currently investigating how long the protective effects of the engineered Tregs will last. Preclinical studies in humanized mice have shown benefits lasting up to one month, but extending this duration is a major focus of ongoing research. The team is also exploring ways to improve the delivery of the engineered cells and determine whether multiple doses could provide longer-lasting protection.

The ultimate goal, as Ferreira explains, is to develop an “off-the-shelf” therapy that combines engineered Tregs with lab-grown beta cells, making it widely accessible to people with T1D at all stages of the disease, even those who have had the condition for many years and have lost most or all of their beta cell function. “We’re trying to develop a therapy that would work for all people with type 1 diabetes at every stage,” he said.

Beyond Diabetes: Implications for Regenerative Medicine

The potential impact of this research extends beyond T1D. Success in reprogramming the immune system to accept transplanted cells could have significant implications for other autoimmune diseases and for the field of regenerative medicine as a whole. The ability to replace damaged or diseased cells with lab-grown replacements, while simultaneously preventing immune rejection, could revolutionize the treatment of a wide range of conditions.

“I think this can change how medicine is done,” Ferreira stated. “Instead of treating symptoms, we can actually replace the missing cells. By doing this work, we are likely to further understand how T1D starts, how it develops and how it can be treated.”

Next Steps: Clinical Trials and Long-Term Monitoring

Translating this promising research into a clinical reality will require further investigation and rigorous testing. The team is preparing for clinical trials to assess the safety and efficacy of the combined cellular therapy in humans. These trials will involve careful monitoring of patients to track the long-term effects of the treatment and to identify any potential side effects. Researchers will also be closely evaluating the durability of the immune protection and exploring strategies to optimize the therapy for individual patients.